12.02.2008 15:09:00
|
Tenderfoot(R) Incision Device, the First Incision Device Designed for Pediatric Blood Draws, Celebrates 20 Years of Proven Clinical Use
Tenderfoot®,
the first incision device developed for heel-stick blood draws from
infants and children, is celebrating two decades of proven clinical use. Tenderfoot
was designed by International Technidyne Corporation (ITC), a
subsidiary of Thoratec Corporation (NASDAQ:THOR). The device is a major
technology advance that standardizes the process of obtaining blood from
infant and pediatric patients making it safer, less traumatic and less
painful than those done with traditional lancet devices.
Introduced in 1988, the patented Tenderfoot device, unlike
traditional lancets that punctured nerve fibers causing bruising and
creating a jagged incision, makes a gentle, sweeping arc incision above
the level of sensitive nerve fibers using a surgical blade that results
in a high-quality blood sample with significantly less pain and trauma.
Once the blade is triggered, it permanently retracts into the device to
eliminate accidental sticks.
"We're proud that Tenderfoot pioneered
improved delivery of healthcare services for infants and toddlers
setting today’s global standards,”
said ITC president, Lawrence Cohen. "Today we’re
celebrating 20 years of proven clinical use and, despite the competition
that comes with success, our continued position as market leader.” Tenderfoot offers a complete line of four incision devices to
cover all pediatric blood draw needs. It is available in four incision
depths and corresponding lengths from micro-preemie through toddler
(0.65mm, 0.85 mm, 1.00 mm and 2.00 mm).
About ITC
ITC is a wholly-owned subsidiary of Thoratec and is a world leader in
the fields of hemostasis management and point-of-care testing with over
35 years of knowledge and experience. ITC develops, manufactures and
markets products in six distinct categories: HEMOCHRON®
point-of-care coagulation instruments and reagents; IRMA TRUpoint®
Blood Analysis System for blood gas and electrolyte testing; AVOXimeter®
co-oximetry devices and cuvettes; skin incision products including
Tenderfoot®,
Tenderlett® and
Surgicutt®; Hgb Pro
Professional Hemoglobin Testing System®;
and the ProTime®
Microcoagulation System for prothrombin time testing at home and for
professional use.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Thoratec Corp.mehr Nachrichten
Keine Nachrichten verfügbar. |